Year: 2001-02

Company: Allecure


The project for AlleCure involves the design and implementation of a primary high throughput screen against a proprietary target, for compounds that affect T-helper cell differentiation (to either the TH1 or TH2 pathway). This is important because the results of the screen have the potential to present therapy for a wide variety of immunological disorders. The basis of the screen will be the detection of certain cytokines that are markers of either TH1 or TH2 differentiated cells. In the process of this primary screen development, different methods involved with the development and performing of this screen will be evaluated on the basis of efficiency as well as cost.